# Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

> **NCT03025945** · NA · COMPLETED · sponsor: **Intuor Technologies, Inc.** · enrollment: 662 (actual)

## Conditions studied

- Cystoid Macular Edema

## Interventions

- **DRUG:** Nepafenac 0.3%
- **DRUG:** Saline Solution

## Key facts

- **NCT ID:** NCT03025945
- **Lead sponsor:** Intuor Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 662 (ACTUAL)
- **Last updated:** 2018-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025945, "Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03025945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*